intravital microscopy in evaluating patients with primary peritoneal, fallopian tube, or stage ia-iv ovarian cancer

Conditions: Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Stage I Ovarian Cancer; Stage IA Ovarian Cancer; Stage IB Ovarian Cancer; Stage IC Ovarian Cancer; Stage II Ovarian Cancer; Stage IIA Ovarian Cancer; Stage IIB Ovarian Cancer; Stage IIC Ovarian Cancer; Stage III Ovarian Cancer; Stage IIIA Ovarian Cancer; Stage IIIB Ovarian Cancer; Stage IIIC Ovarian Cancer; Stage IV Ovarian Cancer

Summary: this pilot clinical trial studies how well intravital microscopy works in evaluating patients with primary peritoneal, fallopian tube, or stage ia-iv ovarian cancer. intravital microscopic evaluation of tumor blood vessels, blood flow, immune cell interactions, and drug uptake may be eventually visualized and may lead to valuable prognostic information.

primary objectives: i. to determine the feasibility of performing intravital microscopy on accessible human ovarian, primary peritoneal and fallopian tube cancers during their standard course of treatment (i.e., surgical debulking). secondary objectives: i. to determine the blood flow velocity of the tumor vessels and tissue penetration of fluorescein as a marker of tumor vessel permeability. outline: patients receive fluorescein sodium injection intravenously (iv). patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery. after completion of study, patients are followed up for 30 days, at 1-3 weeks, and then up to 2 years.

Eligibility criteria:
inclusion criteria: * have an eastern cooperative oncology group (ecog) performance status of =\< 2 * suspicion of gynecological malignancy that requires a standard of care surgical resection in the operating room; * have measurable lesion in the pelvis or abdomen, at a minimum of 0.5 cm in diameter on standard of care pre operative imaging studies (ct, mri or pet scan), * subject or legal representative must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure * serum creatinine \ 1.5 x institutional uln (using cockcroft-gault equation), gfr can also be used in place of creatinine or crcl. exclusion criteria: * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * any known allergy or prior reaction to fluorescein * nursing female subjects * liver dysfunction; normal liver function defined as total bilirubin within normal institutional limits and aspartate aminotransferase (ast) (serum glutamic-oxaloacetic transaminase \[sgot\])/alanine aminotransferase (alt) (serum glutamate pyruvate transaminase \[sgpt\]) =\< 2.5 x institutional upper limit of normal * any condition which in the investigator's opinion deems the subject an unsuitable candidate to undergo observational study (may also include preoperative testing results including electrocardiography (ekg), chest x-ray, or pulmonary function tests that preclude a wide excision in the operating room)